Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S. Davids, Ian W. Flinn, Owen A. O’Connor et al.|Blood Advances|2021Cited by 21
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer TherapyPrathap Nagaraja Shastri, Alison Betts, Marc W. Retter et al.|Clinical Pharmacology & Therapeutics|2024Cited by 9